KAFDITYVRLKF 是一种选择性的、竞争性的整合素 αvβ3 结合剂,可诱导 MMP-9 产生,阻断单核细胞迁移,促进黑色素瘤细胞迁移,保护神经元,改善运动与认知功能,并可用于黑色素瘤和帕金森病的相关研究。
产品编号: MS-M25114 CAS No.: 208116-26-1 分子式: C73H113N17O17 分子量: 1500.81
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

KAFDITYVRLKF 是一种选择性的、竞争性的整合素 αvβ3 结合剂,可诱导 MMP-9 产生,阻断单核细胞迁移,促进黑色素瘤细胞迁移,保护神经元,改善运动与认知功能,并可用于黑色素瘤和帕金森病的相关研究。

生物实验数据

生物活性 KAFDITYVRLKF is a selective and competitive integrin αvβ3 binding agent that induces MMP-9 production, blocks monocyte migration, promotes melanoma cell migration, protects neurons, improves motor and cognitive function, and can be used in research related to melanoma and Parkinson's disease.
IC50 & Target

MMP-9

 

αvβ3

 

体外研究
(In Vitro)

KAFDITYVRLKF (100 μg/mL; 5 h) 在 Boyden 小室实验中可强烈促进 B16-F10 小鼠黑色素瘤细胞的迁移。
KAFDITYVRLKF (2-20 μg/mL; 16 h) 可呈剂量依赖性促进 B16-F10 小鼠黑色素瘤细胞分泌 MMP-9,在 20 μg/mL 作用 16 h 后分泌量约提升 8 倍,但对 MMP-2 的生成无影响。
KAFDITYVRLKF 可选择性结合 αvβ3 并减少单核细胞穿过内皮细胞的迁移。

Cell Migration Assay

Cell Line: B16-F10 mouse melanoma cells
Concentration: 100 μg/mL
Incubation Time: 5 h
Result: Stimulated migration of B16-F10 cells, with the strongest enhancement activity among tested peptides.
Showed activity comparable to that of peptide A-13.
体内研究
(In Vivo)

KAFDITYVRLK (0.2 mg;静脉注射;单次给药) 可显著增强雌性 C57BL6/N 小鼠体内 B16-F10 黑色素瘤细胞的实验性肺转移,使平均肺集落数增加至 481,较对照组水平提升 3 倍。
KAFDITYVRLKF (2 mg/100 g;静脉注射;每日 1 次;连续 14 天) 可保护多巴胺能和 γ-氨基丁酸能神经元,减轻神经炎症和血脑屏障破坏,并改善 MPTP (MS-O89430) 诱导的帕金森病小鼠的运动及认知功能。
KAFDITYVRLKF (2 mg/100 g;静脉注射;每日 1 次;连续 14 天) 可保护多巴胺能和 γ-氨基丁酸能神经元,减轻神经炎症和血脑屏障破坏,并改善 6-OHDA (MS-Q40892) 诱导的帕金森病大鼠的运动及认知功能。

Animal Model: Sprague-Dawley (male, 200-250 g, 6-OHDA-induced dopaminergic neuron degeneration)
Dosage: 2 mg/100 g
Administration: i.v.; once daily; 14 consecutive days
Result: Ameliorated locomotor impairment in the open field test (increased total traveled distance and mean velocity relative to vehicle-treated 6-OHDA rats).
Improved motor coordination in the rotarod test (increased time spent on the rotating device relative to vehicle-treated 6-OHDA rats).
Rescued spatial cognitive impairment in the novel object recognition test (increased discrimination score relative to vehicle-treated 6-OHDA rats).
Reduced synchronous contraction of agonist and antagonist hindlimb muscles relative to vehicle-treated 6-OHDA rats.
Reduced serum IL-6 and ROS levels relative to vehicle-treated 6-OHDA rats.
Reduced CNS inflammatory cell infiltration.
Suppressed microglial activation (reduced Iba-1+ cell count in striatum and substantia nigra relative to vehicle group).
Reduced astrocyte activation (reduced GFAP+ cell count relative to vehicle group).
Downregulated pro-inflammatory mediators NF-κB and COX-2 in striatal and nigral tissues relative to vehicle group.
Reduced blood vessel leakage and BBB permeability relative to vehicle-treated 6-OHDA rats.
Increased expression of tight junction protein ZO-1 relative to vehicle group.
Increased NG2+ pericyte area density relative to vehicle group.
Increased survival of TH+ dopaminergic neurons in the striatum and substantia nigra relative to vehicle group.
Restored GABA transporter-positive neuron count in the striatum relative to vehicle group.
Restored CHAT+ neuron count in striatal and nigral tissues relative to vehicle group.
Reduced expression of neuronal apoptosis marker active caspase-3 relative to vehicle group.
Restored expression of synapse-associated protein Syn relative to vehicle group.
Reduced expression of PD progression marker pS129-α-syn relative to vehicle group.
Upregulated expression of neuronal activation marker cFos relative to vehicle group.
Suppressed upregulation of phospho-DARPP-32 relative to vehicle group.
Reversed downregulation of prodynorphin and upregulation of preproenkephalin relative to vehicle group.

化学信息

分子量 1500.81
分子式 C73H113N17O17
CAS No. 208116-26-1

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础